Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation.

Luo G, Li D, Peng J, Liu R, Meng Y, Ward R, Zhang Y, Zhang X, Cui F, Wang J, Yang X, Chen M, Xu Y, Chen S, Jiang W, Zhang L, Li Y, Yang Y, Xiang C, Guo X, Dai J, Sang J, Xu TR, An S